[{"id":"70cf91ce-5494-4e3c-8936-16d7a4476273","acronym":"TORCH-R","url":"https://clinicaltrials.gov/study/NCT05628038","created_at":"2025-03-03T11:15:37.220Z","updated_at":"2025-03-03T11:15:37.220Z","phase":"Phase 2","brief_title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","source_id_and_acronym":"NCT05628038 - TORCH-R","lead_sponsor":"Fudan University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • irinotecan • leucovorin calcium • Tomudex (raltitrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 11/30/2022","start_date":" 11/30/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-10-01"},{"id":"e7d9fe50-ff91-4c29-ab5e-b8cc0e63a062","acronym":"","url":"https://clinicaltrials.gov/study/NCT05426811","created_at":"2022-06-22T22:54:05.190Z","updated_at":"2024-07-02T16:36:08.125Z","phase":"Phase 1/2","brief_title":"Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients","source_id_and_acronym":"NCT05426811","lead_sponsor":"China Medical University, China","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib) • Tomudex (raltitrexed)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2022-06-29"},{"id":"1c0ea052-dc8a-413f-8c02-39fcfddffd71","acronym":"","url":"https://clinicaltrials.gov/study/NCT04241731","created_at":"2022-06-29T09:02:18.833Z","updated_at":"2024-07-02T16:36:25.588Z","phase":"Phase 2","brief_title":"A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer","source_id_and_acronym":"NCT04241731","lead_sponsor":"Jiangsu Cancer Institute \u0026 Hospital","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tomudex (raltitrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/28/2019","start_date":" 11/28/2019","primary_txt":" Primary completion: 11/28/2021","primary_completion_date":" 11/28/2021","study_txt":" Completion: 11/28/2021","study_completion_date":" 11/28/2021","last_update_posted":"2021-08-30"},{"id":"4e0ffb47-fabe-4e8b-a9de-300a29ee680f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499586","created_at":"2021-01-18T21:33:20.093Z","updated_at":"2024-07-02T16:36:42.327Z","phase":"Phase 2","brief_title":"A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer","source_id_and_acronym":"NCT04499586","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Tomudex (raltitrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-08-05"},{"id":"479197ad-1bd6-4605-b44e-867b9f038979","acronym":"","url":"https://clinicaltrials.gov/study/NCT03823079","created_at":"2021-01-18T18:53:04.143Z","updated_at":"2024-07-02T16:37:03.366Z","phase":"Phase 2","brief_title":"Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia","source_id_and_acronym":"NCT03823079","lead_sponsor":"Fudan University","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Tomudex (raltitrexed)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 02/01/2020","study_completion_date":" 02/01/2020","last_update_posted":"2019-01-30"},{"id":"2a18b389-bb1e-4b11-9a58-ae4a0ebee432","acronym":"HEARTO","url":"https://clinicaltrials.gov/study/NCT01348412","created_at":"2024-01-07T00:16:56.371Z","updated_at":"2024-07-02T16:37:08.945Z","phase":"Phase 2","brief_title":"Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure","source_id_and_acronym":"NCT01348412 - HEARTO","lead_sponsor":"Centre Georges Francois Leclerc","biomarkers":" MELTF","pipe":"","alterations":" ","tags":["MELTF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Tomudex (raltitrexed)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 12/15/2010","start_date":" 12/15/2010","primary_txt":" Primary completion: 12/15/2010","primary_completion_date":" 12/15/2010","study_txt":" Completion: 04/18/2018","study_completion_date":" 04/18/2018","last_update_posted":"2018-07-16"},{"id":"dff38369-0cc6-45bc-8ba0-465d9d25bb5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02618356","created_at":"2021-01-18T12:43:19.052Z","updated_at":"2024-07-02T16:37:17.384Z","phase":"Phase 2","brief_title":"Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer","source_id_and_acronym":"NCT02618356","lead_sponsor":"Fudan University","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Teysuno (gimeracil/oteracil/tegafur) • Tomudex (raltitrexed)"],"overall_status":"Unknown status","enrollment":" Enrollment 82","initiation":"Initiation: 12/25/2015","start_date":" 12/25/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2017-10-02"}]